Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

The tumor microenvironment (TME) is connected to immunotherapy responses, but it
remains unclear how cancer cells and host tissues differentially influence the immune …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

A major challenge in human genetics is to identify the molecular mechanisms of trait-
associated and disease-associated variants. To achieve this, quantitative trait locus (QTL) …

Tumor heterogeneity is one of the hallmarks of cancer and a challenge in the field of
oncology. Tumor heterogeneity is the main cause of drug resistance, leading to therapeutic …

During the course of tumorigenesis and subsequent metastasis, malignant cells gradually
diversify and become more heterogeneous. Consequently, the tumor mass might be …

Artificial intelligence (AI) is a transformative technology that is capturing popular imagination
and can revolutionize biomedicine. AI and machine learning (ML) algorithms have the …

The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …

Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy
in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may …